BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
July 16, 2008
View Archived Issues
Novel therapeutic agents for neurologic disorders reported in recent patents
Read More
Results from animal studies indicate potential use for AMN-082 in treating inflammatory pain
Read More
Allergan acquires acne treatment Aczone from QLT for USD 150 million
Read More
Rottapharm's new analgesic CR-4056 modulates neurotransmitter release in vitro
Read More
New anticancer agents described in recent patent literature
Read More
Recent patents disclose new treatment options for metabolic disorders
Read More
Motesanib diphosphate induces partial responses in patients with thyroid cancer
Read More
Glenmark's neuropathic pain candidate, GRC-10693, to enter phase I trials
Read More
Jerini receives European approval for Firazyr for hereditary angioedema
Read More
Novo Nordisk files NDA for liraglutide in Japan
Read More
OSI initiates phase I OSI-027 in patients with advanced solid tumors or lymphoma
Read More
Phase II RX-3341 trial initiated in complicated skin and skin structure infections
Read More
Infinity discontinues enrollment in phase II IPI-504 study in prostate cancer
Read More
Theravance presents positive phase II results for GSK-961081 in COPD
Read More
Sigma-Tau's 5-HT6 receptor ligand shows antidepressant-like activity in vivo
Read More
DiaMedica meets primary endpoint from phase II trial of DM-83 in type 2 diabetes
Read More
Perlegen out-licenses 6 patented complementary technologies for genetic diagnostics
Read More
Pro-Pharmaceuticals requests pre-IND meeting with FDA to define regimen for EZ-646
Read More
AMT enters collaboration with St. Jude Children's Hospital for hemophilia B gene therapy
Read More
Health Canada approves SyntheMed's Repel-CV for open heart surgery in pediatric patients
Read More
FDA approves Roxane's NDA for morphine sulfate tablets and oral solution
Read More
Oramed completes equity financing of USD 5 million through private placement
Read More
Collegium closes USD 20 million series D equity financing
Read More
Actonel and Benet receive additional indication approval in Japan for Paget's disease
Read More
